Maxygen Granted Approval for Factor VIIa Trial in UK
Posted on: Thursday, 12 June 2008, 12:00 CDT
Maxygen has filed a clinical trial authorization and received the necessary approvals in the UK to initiate a first-in-human Phase I trial of Maxy-VII in hemophilia patients.
Maxy-VII is the company's next-generation Factor VIIa protein for the treatment of hemophilia. Patient dosing is on schedule to begin in the second half of 2008.
Russell Howard, CEO of Maxygen, said: "I'd like to congratulate our clinical team for meeting its goal of filing a clinical trial authorization in the first half of 2008, and for obtaining a rapid approval.
In addition to expedient management of Maxy-VII, the team has kept the Maxy-G34 G-CSF Phase IIa program moving forward on schedule. We expect to be able to share preliminary results from that program by the end of 2008."
Source: Datamonitor
Related Articles
- Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
- Bostwick Wins Approval to Initiate Phase I/II Prostate Cancer Trial
- Bayer Acquires Maxygen's Hemophilia Program Assets
- Bayer HealthCare and Maxygen Announce Hematology Agreement
- Maxygen Receives Approval for Clinical Trial of Factor VIIa in the United Kingdom
- Novelos Announces Presentation of Encouraging Results in Phase 2 Ovarian Cancer Trial at 2008 ASCO Meeting By MGH and Dana-Farber/Harvard Cancer Centers
- ZIOPHARM Announces Interim Results in ZIO-101 Phase I Solid Tumor Cancer Trial; Clinical Activity in Several Cancers
- WorldHeart Expands RELIANT Trial Clinical Executive Committee
- Eugene awarded 2008 U.S. Olympic trials
 |
 |
User Comments (0)
RSS Feeds